Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

dc.contributor.author
von Massow, Georg
dc.contributor.author
Garcia-Cehic, D.
dc.contributor.author
Gregori i Font, Josep
dc.contributor.author
Rodríguez Frías, Francisco
dc.contributor.author
Macià, María Dolores
dc.contributor.author
Escarda, Ana
dc.contributor.author
Esteban Mur, Juan Ignacio
dc.contributor.author
Quer, Josep
dc.date.issued
2019
dc.identifier
https://ddd.uab.cat/record/222733
dc.identifier
urn:10.2147/IDR.S195441
dc.identifier
urn:oai:ddd.uab.cat:222733
dc.identifier
urn:scopus_id:85066992952
dc.identifier
urn:articleid:11786973v12p947
dc.identifier
urn:oai:egreta.uab.cat:publications/dc181cf6-7546-46d8-bd70-d3935e5d0cdc
dc.identifier
urn:pmid:31118701
dc.identifier
urn:pmc-uid:6499441
dc.identifier
urn:pmcid:PMC6499441
dc.identifier
urn:oai:pubmedcentral.nih.gov:6499441
dc.description.abstract
Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.
dc.format
application/pdf
dc.language
eng
dc.publisher
dc.relation
Ministerio de Economía y Competitividad IDI-20151125
dc.relation
Instituto de Salud Carlos III PI15/00856
dc.relation
Instituto de Salud Carlos III PI15/00829
dc.relation
Instituto de Salud Carlos III PI16/00337
dc.relation
Infection and drug resistance ; Vol. 12 (2019), p. 947-955
dc.rights
open access
dc.rights
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
dc.rights
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Subtype
dc.subject
Direct-acting antivirals
dc.subject
HCV
dc.subject
Genotype 1
dc.title
Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
dc.type
Article


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)